Fig. 4

IGF-2 did not rescue or improve gait deficits in Ube3a^mat−/pat+ mice. a Compared to wildtype littermates (Ube3a^mat+/pat+; mat+/pat+), Ube3a^mat−/pat+ (mat-/pat+) mice exhibited wider stances while treadmill walking, which were reduced by IGF-2 treatment in the forelimbs but unaffected by IGF-2 in the hindlimbs. b Stride lengths were increased in mat-/pat+ mice and were further increased by IGF-2 while c the reduced stride frequency of mat-/pat+ mice was further decreased in forelimbs by IGF-2. d IGF-2 had no effect on the elevated forelimb propulsion time of mat-/pat+ mice and led to further elevation of the increased hindlimb propulsion time. e Swing time was elevated in mat-/pat+ mice, regardless of IGF-2 treatment and f brake time was normal in mat-/pat+ mice and unchanged by IGF-2. Data are expressed as mean ± S.E.M. n = 17–24 mice/group. a, c *Genotype, p < 0.05, main effect of genotype via two-way ANOVA (per limb set); *Treatment, p < 0.05, main effect of treatment via two-way ANOVA (per limb set). a-f *p < 0.05, Tukey’s multiple comparisons test following two-way ANOVA (per limb set)